Project Grant R01CA312130
Award Date 6/2/26
Completion Date 5/31/31
Dollars Obligated $582K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90033, USA
Similar Awards
- Federal Project Grant Award Summary The University of Southern California received a $560,863 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded June 2, 2026, with a completion date of May 31, 2031. This research project investigates the role of p73-mediated Death Receptor 5 (DR5) induction in therapeutic response to cyclin-dependent kinase (CDK) inhibition, with particular focus on colorectal cancer treatment. The research...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Southern California $479,234 under the Cancer Biology Research program (CFDA 93.396) to conduct a comprehensive research initiative examining nonsense-mediated mRNA decay (NMD) mechanisms in cancer. Spanning from May 15, 2026, to April 30, 2031, this project delivers fundamental research services aimed at understanding NMD's regulatory functions beyond its conventional role in degrading faulty mRNA...
- Federal Grant Award Summary The University of Southern California received a $680,452 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective June 9, 2026, with a completion date of May 31, 2029. This research initiative focuses on discovering novel small-molecule compounds that selectively target the BMAL1:CLOCK circadian regulatory complex for cancer therapeutic applications. The project addresses a significant gap in drug...
- Federal Project Grant Award Summary The University of Southern California received a $1,283,835 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded July 1, 2025, with a completion date of June 30, 2030. This grant supports the development and translational advancement of IMT-423 (MHC-II-Restricted CT83-Specific CD4-Dependent TCRM50A-STEM2) T cells, a novel T cell receptor (TCR)-engineered CD4+ T cell immunotherapy...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Southern California a $3,036,844 Project Grant on August 11, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate a wireless thermos-activator device for controllable solid tumor immunotherapy. The project addresses critical limitations in Chimeric Antigen Receptor (CAR) T cell therapy by creating a portable, patient-friendly alternative to MRI-guided...
- Federal Project Grant Award Summary The University of Southern California received a $137,459 Cancer Research Manpower (CFDA 93.398) award from the National Cancer Institute, effective June 1, 2026 through May 31, 2029. This K01 mentored research development award supports an integrated training and research project focused on developing a spatially controlled priming system for chimeric antigen receptor (CAR) T cell therapy in solid tumors. The award funds research to engineer a focused...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $501,422 Project Grant under the Cancer Biology Research program (CFDA 93.396) commencing May 1, 2026, with completion targeted for April 30, 2031. This award supports fundamental research to advance understanding of synthetic lethal (SL) vulnerabilities in specific cancer subtypes, with the ultimate objective of developing novel precision oncology therapeutics. The research...
- Federal Grant Award Summary The University of Southern California received a $506,018 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective June 1, 2026 through January 31, 2030. The award funds research to elucidate the structural and molecular basis of DNA Polymerase Theta (POLθ) functions in DNA repair. The research integrates structural biology, biochemistry, and cell biology...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a $584,521 Project Grant on August 8, 2025, under the Cancer Treatment Research program (CFDA 93.395) to investigate subclonal determinants of radiation response in soft tissue sarcomas. The research will deliver three primary products: (1) identification and validation of epigenetic changes, including DNA methylation and chromatin accessibility alterations, that confer radioresistance to...